Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies
Open Access
- 12 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Health and Quality of Life Outcomes
- Vol. 11 (1), 42
- https://doi.org/10.1186/1477-7525-11-42
Abstract
Background: Selection of an appropriate patient-reported outcome (PRO) instrument for a clinical trial requires knowledge of the instrument’s responsiveness to detecting treatment effects. The purpose of this study was to examine the responsiveness of two health-related quality of life (HRQL) instruments used in clinical trials involving HIV-infected adults: the HIV-targeted Medical Outcomes Study HIV Health Survey (MOS-HIV), and a generic measure, the EuroQol-5D (EQ-5D).Methods: A systematic review identified clinical trials using the MOS-HIV or EQ-5D to assess outcomes for HIV-infected adults. Data abstracted from each study included study type, treatment regimen(s), PRO results, and effect size (either reported or calculated). Effect size was calculated as the difference between baseline and follow-up mean scores divided by the baseline standard deviation. Magnitude was categorized as small (d=0.20), medium (d=0.50), and large (d=0.80).Results: Between 2005 and 2010, the MOS-HIV was administered in 12 trials. Significant differences were observed between groups and over time in physical health summary (PHS) and mental health summary (MHS) scores (P<0.05) in subjects switching therapy after experiencing Grade-2 adverse events. Effect sizes were medium (0.55 and 0.49 for PHS and MHS, respectively) among treatment-naïve adults beginning therapy (two studies), but negligible among treatment-experienced adults (0.04 and 0.13 for PHS and MHS, respectively; three studies). The EQ-5D was used in five trials between 2001 and 2010. It was responsive to occurrences of adverse events and opportunistic infections, with small-to-medium effect sizes (range 0.30–0.50) in each of its five dimensions.Conclusions: A systematic review of PRO study results showed both the MOS-HIV and EQ-5D were responsive to changes between groups and/or over time in treatment-naïve HIV-infected patients. These instruments may be used either individually or together in clinical trials to measure changes in HRQL.Keywords
This publication has 24 references indexed in Scilit:
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Healthcare infrastructure and emotional support are predictors of CD4 cell counts and quality of life indices of patients on antiretroviral treatment in Free State Province, South AfricaAIDS Care, 2009
- The Impact of Combination Antiretroviral Therapy and its Interruption on Anxiety, Stress, Depression and Quality of Life in Thai PatientsThe Open AIDS Journal, 2009
- T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapyBiologics: Targets and Therapy, 2008
- Efficacy of Epoetin Alfa Administered Every 2 Weeks to Maintain Hemoglobin and Quality of Life in Anemic HIV-Infected PatientsAIDS Research and Human Retroviruses, 2008
- The Combined Effect of Relaxation Response and Acupuncture on Quality of Life in Patients with HIV: A Pilot StudyThe Journal of Alternative and Complementary Medicine, 2007
- Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural UgandaAIDS Care, 2007
- Quality of Life and Tolerability After Administration of Enfuvirtide with a Thin-Walled Needle: QUALITÉ StudyHIV Research & Clinical Practice, 2007
- Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infectionAIDS, 2006
- A power primer.Psychological Bulletin, 1992